Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia
Saleh Alghamdi, Bassant Barakat, Ilhem Berrou, Abdulhakim Alzahrani, Abdul Haseeb, Mohamed Anwar Hammad, Sirajudheen Anwar, Abdulmajeed Abdulghani A Sindi, Hussain A Almasmoum, Mohammad Albanghali
Antibiotics, doi:10.3390/antibiotics10040365
The aim of this study was to assess the clinical effectiveness of Hydroxychloroquine-based regimens versus standard treatment in patients with the coronavirus disease admitted in 2019 to a hospital in Saudi Arabia. A comparative observational study, using routine hospital data, was carried out in a large tertiary care hospital in Al Baha, Saudi Arabia, providing care to patients with COVID-19 between April 2019 and August 2019. Patients were categorized into two groups: the Hydroxychloroquine (HCQ) group, treated with HCQ in a dose of 400 mg twice daily on the first day, followed by 200 mg twice daily; the non HCQ group, treated with other antiviral or antibacterial treatments according to protocols recommended by the Ministry of Health (MOH) at the time. The primary outcomes were the length of hospital stay, need for admission to the intensive care unit (ICU), time in ICU, and need for mechanical ventilation. Overall survival was also assessed. 568 patients who received HCQ (treatment group) were compared with 207 patients who did not receive HCQ (control group). HCQ did not improve mortality in the treated group (7.7% vs. 7.2%). There were no significant differences in terms of duration of hospitalization, need for and time in ICU, and need for mechanical ventilation among the groups. Our study provides further evidence that HCQ treatment does not reduce mortality rates, length of hospital stay, admission and time in ICU, and need for mechanical ventilation in patients hospitalized with COVID-19.
Conflicts of Interest: The authors declare no conflict of interest.
References
Almaghlouth, Islam, Alamro, Alsultan, Alfadda et al., Mapping COVID-19 related research from Saudi Arabia, a scoping review: Between reality and dreams, Saudi Med. J,
doi:10.15537/smj.2020.8.25163Almazrou, Almalki, Alanazi, Alqahtani, Alghamd, Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study, Saudi Pharm. J,
doi:10.1016/j.jsps.2020.09.019Altakarli, Emergence of COVID-19 Infection: What Is Known and What Is to Be Expected-Narrative Review Article, Dubai Med. J,
doi:10.1159/000506678Casadevall, Pirofski, The convalescent sera option for containing COVID-19, J. Clin. Investig
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial, MedRxiv,
doi:10.1101/2020.03.22.20040758Chorin, Dai, Shulman, Wadhwani, Bar-Cohen et al., The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin, Nat. Med,
doi:10.1038/s41591-020-0888-2Drew, Ackerman, Funk, Gibler, Kligfield et al., Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement from the American Heart Association and the American College of Cardiology Foundation, J. Am. Coll. Cardiol,
doi:10.1016/j.jacc.2010.01.001Esper, Weibel, Ferguson, Landry, Kahn, Evidence of a Novel Human Coronavirus That is Associated with Respiratory Tract Disease in Infants and Young Children, J. Infect. Dis,
doi:10.1086/428138Gautret, Lagier, Parola, Hoang, Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2020.105949Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med
Grandvuillemin, Fresse, Cholle, Yamani, Dautriche, Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data, Therapie,
doi:10.1016/j.therap.2020.05.001Hancox, Hasnain, Vieweg, Crouse, Baranchuk, Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports, Ther. Adv. Infect. Dis,
doi:10.1177/2049936113501816Ip, Ahn, Zhou, Goy, Hansen et al., Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study, BMC Infect. Dis,
doi:10.1186/s12879-021-05773-wJuurlink, Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection, Can. Med. Assoc. J,
doi:10.1503/cmaj.200528Mahevas, Tran, Roumier, Chabrol, Paule et al., Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: Observational comparative study using routine care data, BMJ,
doi:10.1136/bmj.m1844Mcintosh, Dees, Becker, Kapikian, Chanock, Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.57.4.933Mega, Feyissa, Bosho, Goro, Negera, The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis, Can. Respir. J,
doi:10.1155/2020/4312519Pak, Adegboye, Adekunle, Rahman, Mcbryde et al., Economic Consequences of the COVID-19 Outbreak: The Need for Epidemic Preparedness, Front. Public Heath,
doi:10.3389/fpubh.2020.00241Pascarella, Strumia, Piliego, Bruno, Del Buono et al., COVID-19 diagnosis and management: A comprehensive review, J. Intern. Med,
doi:10.1111/joim.13091Picot, Marty, Bienvenu, Blumberg, Dupouy-Camet et al., Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19, One Health,
doi:10.1016/j.onehlt.2020.100131Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State, J. Am. Med. Assoc,
doi:10.1001/jama.2020.8630Sarma, Kaur, Kumar, Mahendru, Avti et al., Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis, J. Med. Virol,
doi:10.1002/jmv.25898Shah, Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing, J. Clin. Pharm. Ther,
doi:10.1111/jcpt.13267Shah, Stonier, Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead, J. Clin. Pharm. Ther,
doi:10.1111/jcpt.12759Shen, Wang, Zhao, Yang, Li et al., Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma, J. Am. Med. Assoc,
doi:10.1001/jama.2020.4783Stöhr, A multicentre collaboration to investigate the cause of severe acute respiratory syndrome, Lancet
Tripathy, Dassarma, Roy, Chabalala, A review on possible modes of action of chloroquine/hydroxychloroquine: Repurposing against SAR-CoV-2 (COVID-19) pandemic, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2020.106028Zaki, Van Boheemen, Bestebroer, Osterhaus, Fouchier, Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia, N. Engl. J. Med,
doi:10.1056/NEJMoa1211721
